Drug Trial Radar · NCT03819465
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
175
Actual
Start
Dec 27, 2018
Primary completion
May 23, 2023
Study completion Jul 1, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
DurvalumabDrug
Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
DanvatirsenDrug
Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
OleclumabDrug
Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
MEDI5752Drug
MEDI5752 IV Every 3 weeks (q3w)
PemetrexedDrug
Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
CarboplatinDrug
Carboplatin IV Day 1 of each 21-day cycle
GemcitabineDrug
Gemcitabine IV Days 1 and 8 of each 21-day cycle
CisplatinDrug
Cisplatin IV Day 1 of each 21-day cycle
Nab-paclitaxelDrug
Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
AZD2936Drug
AZD2936 IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of AEs by CTCAE v5.0Time frame: From informed consent until the safety follow-up visit 3 months after the last dose of study drug, or until the final data cut-off (DCO) date, whichever is earlier.
Locations
41 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Iowa City, Iowa
Research Site
Pittsburgh, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Edegem, Belgium
Research Site
Bialystok, Poland
Research Site
Bydgoszcz, Poland
Research Site
Gdansk, Poland
Research Site
Grudziądz, Poland
Research Site
Lodz, Poland
Research Site
Olsztyn, Poland
Research Site
Tomaszów Mazowiecki, Poland
Research Site
Warsaw, Poland
Research Site
Wroclaw, Poland
Research Site
Krasnoyarsk, Russia
Research Site
Moscow, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Cheongju-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Seville, Spain
Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan, Taiwan
Research Site
Bangkok, Thailand
Research Site
Bangkok, Thailand
Research Site
Chiang Mai, Thailand
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.